Molecules with extended half-lives, compositions and uses thereof

US8323962B2 · kind B2 · utility

Assignees

• MedImmune Limited · US
• The Board of Regents of the University of Texas System · US

Inventors

• William Dall'Acqua · Gaithersburg, US
• Leslie S. Johnson · Germantown, US
• Elizabeth Sally Ward · Cambridge, GB

Key dates

• Filing date: Jul 27, 2011
• Grant date: Dec 4, 2012
• Expiry date: Jul 27, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S435/81
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.